ArticleLife (Basel, Switzerland)2025
Cytokine Gene Expression and Treatment Impact on MRI Outcomes in Jordanian Patients with Multiple Sclerosis.
Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic Outcomes of Fingolimod and Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis: A Real-World Study from Jordan.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCentral nervous system autoimmune disorders, like multiple sclerosis (MS), are chronic conditions where cytokines contribute significantly to the regulation of inflammation. The diagnosis, progression, and treatment effectiveness of MS are assessed through laboratory tests and clinical evaluation, as well as imaging.
methodThis study included 40 healthy individuals as a control group and 75 MS patients, divided into two groups: 45 MS patients receiving fingolimod treatment (MSW) and 30 patients taking other medications (MSOs). Blood samples (3 mL) were collected from all participants, and the mRNA relative expression of cytokine genes (
resultsThe MSO patient group displayed higher mRNA expressions of
conclusionsFingolimod demonstrated greater effectiveness in improving MS patients' conditions, possibly due to its impact on cytokine expression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.